Regulatory risk Recent allegations about use and sharing of genetic information in consumer DNA testing suggest heightened regulatory scrutiny and potential privacy concerns. This creates an opportunity to position privacy-compliant, transparent data handling and consent management services to Gateway Genomics or its partners.

Acquisition synergies Gateway Genomics was acquired by Myriad Genetics for 67.5M, indicating strategic consolidation in prenatal genetics. Develop a targeted pitch around integration support, data interoperability, and scalable analytics solutions that align with a portfolio already under a larger genomic group.

Growth momentum Recognized as an Inc 5000 Fastest Growing Company multiple years and a track record of rapid expansion, coupled with a lean headcount, suggests openness to scalable external services such as cloud infrastructure, outsourced R&D support, and partner-led distribution programs.

Direct-to-consumer focus Strong consumer-facing prenatal testing brand with SneakPeek products indicates demand for consumer data platforms, marketing analytics, and privacy-preserving data sharing capabilities that could be offered as B2C-friendly software or services to extend reach.

Strategic channel expansion Experience with direct-to-consumer launches and brand affiliations points to opportunity in partner ecosystems, channel development, and affiliate program optimization—services around channel enablement, partner onboarding, and performance tracking could drive growth.